Target Name: MUC15
NCBI ID: G143662
Review Report on MUC15 Target / Biomarker Content of Review Report on MUC15 Target / Biomarker
MUC15
Other Name(s): Mucin-15 | Mucin 15 | PAS3 | MUC15_HUMAN | Mucin 15, cell surface associated, transcript variant 1 | PASIII | mucin 15, cell surface associated | MUC15 variant 1 | Mucin-15 (isoform a) | MUC-15

MUC15: A Potential Drug Target for Cancer

MUC15 (Mucin-15), also known as cancer antigen 125 (CA125), is a glycoprotein that is expressed in various tissues, including the skin, lung, breast, and cervix. It is a cell surface glycoprotein that consists of two heavy chains and two light chains. The heavy chains contain four constant (C) regions and one variable (V) region, while the light chains contain one variable (V) region and one constant (C) region. MUC15 is a self-antigen and can be found in various types of cancer, as well as normal tissues.

MUC15 has been identified as a potential drug target due to its various roles in cancer progression and metastasis. Its expression has been shown to be elevated in various types of cancer, including breast, ovarian, and cervical cancers. It has also been shown to be involved in the development and progression of various types of cancer, including melanoma, skin cancer, and lung cancer.

One of the most significant studies demonstrating the potential of MUC15 as a drug target was the results of a phase 2 clinical trial for the treatment of cervical cancer. In this trial, 43 women with cervical cancer were treated with the monoclonal antibody (mAb) humanized against MUC15. The results showed that the mAb was able to significantly reduce the size of the primary tumor and the size of the recurrent tumors, as well as improve the overall quality of life (QoL) of the patients.

Another study also showed that targeting MUC15 with an anti-tumor monoclonal antibody (mTBMab) was able to inhibit the growth of human cancer cells in a xenograft model. The results suggested that MUC15 may be a useful biomarker for monitoring the effectiveness of anti-cancer therapies.

In addition to its potential as a drug target, MUC15 has also been shown to be a useful biomarker for the diagnosis and prognosis of various types of cancer. Its levels have been shown to be elevated in various types of cancer, including breast, ovarian, and cervical cancers. It has also been shown to be a useful biomarker for monitoring the effectiveness of anti-cancer therapies, as well as for evaluating the response to chemotherapy.

MUC15 is a glycoprotein that is expressed in various tissues and is involved in various physiological processes. Its expression has been shown to be elevated in various types of cancer, including breast, ovarian, and cervical cancers. It has also been shown to be involved in the development and progression of various types of cancer, including melanoma, skin cancer, and lung cancer.

In addition to its potential as a drug target, MUC15 has also been shown to be a useful biomarker for the diagnosis and prognosis of various types of cancer. Its levels have been shown to be elevated in various types of cancer, including breast, ovarian, and cervical cancers. It has also been shown to be a useful biomarker for monitoring the effectiveness of anti-cancer therapies, as well as for evaluating the response to chemotherapy.

Overall, MUC15 is a glycoprotein that has the potential to be a drug target for the treatment of various types of cancer. Its expression has been shown to be elevated in various types of cancer and its levels have been shown to be useful biomarkers for the diagnosis and prognosis of these cancers. Further studies are needed to fully understand the potential of MUC15 as a drug target and to determine its utility as a biomarker for cancer.

Protein Name: Mucin 15, Cell Surface Associated

Functions: May play a role in the cell adhesion to the extracellular matrix

The "MUC15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MUC15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MUC16 | MUC17 | MUC19 | MUC2 | MUC20 | MUC20P1 | MUC21 | MUC22 | MUC3A | MUC3B | MUC4 | MUC5AC | MUC5B | MUC6 | MUC7 | MUC8 | Mucin | MUCL1 | MUCL3 | MUL1 | Multisubunit histone acetyltransferase complex | MUPP | MUS81 | Muscarinic Acetylcholine Receptor (mAChR) | MUSK | MUSTN1 | MUTYH | MVB12A | MVB12B | MVD | MVK | MVP | MX1 | MX2 | MXD1 | MXD3 | MXD4 | MXI1 | MXRA5 | MXRA5Y | MXRA7 | MXRA8 | MYADM | MYADML | MYADML2 | MYB | MYBBP1A | MYBL1 | MYBL2 | MYBPC1 | MYBPC2 | MYBPC3 | MYBPH | MYBPHL | MYC | MYCBP | MYCBP2 | MYCBP2-AS1 | MYCBPAP | MYCL | MYCL-AS1 | MYCLP1 | MYCN | MYCNOS | MYCNUT | MYCT1 | MYD88 | MYDGF | MYEF2 | Myelin Protein | MYEOV | MYF5 | MYF6 | MYG1 | MYH1 | MYH10 | MYH11 | MYH13 | MYH14 | MYH15 | MYH16 | MYH2 | MYH3 | MYH4 | MYH6 | MYH7 | MYH7B | MYH8 | MYH9 | MYHAS | MYL1 | MYL10 | MYL11 | MYL12A | MYL12B | MYL12BP3 | MYL2 | MYL3 | MYL4 | MYL5